<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pilocytic Astrocytoma Treatment Guide</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">
    <style>
        :root {
            --primary: #2c3e50;
            --secondary: #3498db;
            --accent: #9b59b6;
            --light: #ecf0f1;
            --dark: #2c3e50;
            --success: #2ecc71;
            --warning: #f39c12;
            --danger: #e74c3c;
            --info: #17a2b8;
        }
        
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            line-height: 1.6;
            color: #333;
            background-color: #f5f7fa;
            padding: 20px;
        }
        
        .container {
            max-width: 1200px;
            margin: 0 auto;
            background: white;
            border-radius: 10px;
            box-shadow: 0 0 20px rgba(0, 0, 0, 0.1);
            overflow: hidden;
        }
        
        header {
            background: linear-gradient(135deg, var(--primary), var(--secondary));
            color: white;
            padding: 30px;
            text-align: center;
            position: relative;
        }
        
        h1 {
            font-size: 2.8rem;
            margin-bottom: 10px;
        }
        
        .subtitle {
            font-size: 1.2rem;
            opacity: 0.9;
            max-width: 800px;
            margin: 0 auto;
        }
        
        .content {
            padding: 30px;
        }
        
        .section {
            margin-bottom: 40px;
            padding-bottom: 30px;
            border-bottom: 1px solid #eee;
        }
        
        h2 {
            color: var(--secondary);
            font-size: 1.8rem;
            margin-bottom: 20px;
            padding-bottom: 10px;
            border-bottom: 2px solid var(--secondary);
            display: flex;
            align-items: center;
        }
        
        h2 i {
            margin-right: 10px;
            background: var(--secondary);
            color: white;
            width: 40px;
            height: 40px;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
        }
        
        h3 {
            color: var(--accent);
            font-size: 1.4rem;
            margin: 20px 0 15px;
        }
        
        p {
            margin-bottom: 15px;
            font-size: 1.1rem;
        }
        
        .card-container {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }
        
        .card {
            background: white;
            border-radius: 8px;
            overflow: hidden;
            box-shadow: 0 4px 8px rgba(0, 0, 0, 0.1);
            transition: transform 0.3s ease;
            border: 1px solid #eee;
        }
        
        .card:hover {
            transform: translateY(-5px);
            box-shadow: 0 8px 16px rgba(0, 0, 0, 0.1);
        }
        
        .card-header {
            background: var(--primary);
            color: white;
            padding: 15px;
            font-size: 1.2rem;
            font-weight: bold;
        }
        
        .card-body {
            padding: 20px;
        }
        
        .highlight {
            background: linear-gradient(120deg, rgba(155, 89, 182, 0.1), rgba(52, 152, 219, 0.1));
            border-left: 4px solid var(--accent);
            padding: 20px;
            margin: 20px 0;
            border-radius: 0 5px 5px 0;
        }
        
        .clinical-alert {
            background: #e8f4fc;
            border-left: 4px solid var(--info);
            padding: 20px;
            margin: 20px 0;
            border-radius: 0 5px 5px 0;
        }
        
        .table-container {
            overflow-x: auto;
            margin: 20px 0;
        }
        
        table {
            width: 100%;
            border-collapse: collapse;
            background: white;
        }
        
        th, td {
            padding: 12px 15px;
            text-align: left;
            border-bottom: 1px solid #eee;
        }
        
        th {
            background: var(--primary);
            color: white;
            font-weight: bold;
        }
        
        tr:nth-child(even) {
            background-color: #f8f9fa;
        }
        
        .trial-link {
            display: inline-block;
            background: var(--success);
            color: white;
            padding: 8px 15px;
            border-radius: 4px;
            text-decoration: none;
            font-weight: bold;
            margin-top: 10px;
            transition: all 0.3s ease;
        }
        
        .trial-link:hover {
            background: #27ae60;
            transform: translateY(-2px);
        }
        
        .trial-link.emerging {
            background: var(--warning);
        }
        
        .trial-link.emerging:hover {
            background: #e67e22;
        }
        
        .action-plan {
            background: #e8f4fc;
            border-radius: 8px;
            padding: 25px;
            margin: 30px 0;
            border-left: 4px solid var(--secondary);
        }
        
        .action-plan h3 {
            color: var(--secondary);
            margin-top: 0;
        }
        
        .action-plan ol {
            padding-left: 20px;
        }
        
        .action-plan li {
            margin-bottom: 15px;
        }
        
        footer {
            background: var(--dark);
            color: white;
            text-align: center;
            padding: 20px;
            margin-top: 30px;
        }
        
        .note {
            background: #fff8e1;
            border-left: 4px solid #ffc107;
            padding: 15px;
            margin: 20px 0;
            border-radius: 0 4px 4px 0;
        }
        
        .breakthrough {
            background: #d4edda;
            border-left: 4px solid #28a745;
            padding: 15px;
            margin: 20px 0;
            border-radius: 0 4px 4px 0;
        }
        
        .status-badge {
            display: inline-block;
            padding: 4px 8px;
            border-radius: 12px;
            font-size: 0.85rem;
            font-weight: bold;
            margin-left: 10px;
        }
        
        .fda-approved {
            background: #d4edda;
            color: #155724;
        }
        
        .clinical-trial {
            background: #cce5ff;
            color: #004085;
        }
        
        .emerging {
            background: #fff3cd;
            color: #856404;
        }
        
        .preclinical {
            background: #f8d7da;
            color: #721c24;
        }
        
        @media (max-width: 768px) {
            h1 {
                font-size: 2.2rem;
            }
            
            .content {
                padding: 20px;
            }
            
            .card-container {
                grid-template-columns: 1fr;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <header>
            <h1>Pilocytic Astrocytoma Treatment Guide</h1>
            <p class="subtitle">Evidence-Based Precision Medicine Beyond Traditional Chemotherapy</p>
        </header>
        
        <div class="content">
            <div class="section">
                <h2><i class="fas fa-brain"></i> Understanding Pilocytic Astrocytoma</h2>
                <p>Pilocytic Astrocytoma (PA) is the most common pediatric brain tumor with generally favorable outcomes when completely resectable. However, tumors in critical locations like the optic pathway or brainstem present significant treatment challenges. The good news is that PA has predictable genetic drivers that make it an ideal candidate for targeted therapies.</p>
                
                <div class="highlight">
                    <p><strong>Key Genetic Features:</strong> Most PAs are driven by <strong>KIAA1549-BRAF fusion</strong> (50-70% of cases) or <strong>BRAF V600E mutation</strong> (9-10% of cases). Additional targets include <strong>FGFR1 mutations</strong> (15% of adult PA cases) and <strong>NF1-related pathway alterations</strong>.</p>
                </div>
                
                <div class="clinical-alert">
                    <p><strong>Clinical Reality:</strong> Current standard treatment involves surgery when possible, followed by carboplatin/vincristine chemotherapy for unresectable or progressive disease. However, targeted therapies are rapidly becoming first-line alternatives based on recent clinical trial successes.</p>
                </div>
            </div>
            
            <div class="section">
                <h2><i class="fas fa-pills"></i> Current FDA-Approved & Late-Stage Targeted Therapies</h2>
                <p>These evidence-based treatments represent the current standard for molecularly-driven PA therapy:</p>
                
                <div class="card-container">
                    <div class="card">
                        <div class="card-header">MEK Inhibitors <span class="status-badge fda-approved">FDA APPROVED</span></div>
                        <div class="card-body">
                            <p><strong>Drug:</strong> Selumetinib (Koselugo)</p>
                            <p><strong>Target:</strong> BRAF fusions & BRAF V600E mutations</p>
                            <p><strong>Evidence:</strong> 36% response rate in BRAF-aberrant PA, 40% in NF1-associated cases</p>
                            <p><strong>Status:</strong> FDA-approved for NF1 plexiform neurofibromas; Phase 3 trials ongoing for newly diagnosed PA</p>
                            <div class="note">
                                <p><strong>Breakthrough:</strong> Children's Oncology Group is now comparing selumetinib to standard chemotherapy as first-line treatment</p>
                            </div>
                        </div>
                    </div>
                    
                    <div class="card">
                        <div class="card-header">Dual BRAF/MEK Inhibition <span class="status-badge clinical-trial">CLINICAL TRIALS</span></div>
                        <div class="card-body">
                            <p><strong>Drugs:</strong> Dabrafenib + Trametinib</p>
                            <p><strong>Target:</strong> BRAF V600E mutations specifically</p>
                            <p><strong>Advantage:</strong> More potent and durable responses than single-agent therapy</p>
                            <p><strong>Evidence:</strong> Dramatic responses reported in adult PA cases; pediatric trials expanding</p>
                            <a href="https://clinicaltrials.gov/search?cond=pilocytic%20astrocytoma&term=dabrafenib" class="trial-link" target="_blank">Search Current Trials</a>
                        </div>
                    </div>
                </div>
                
                <div class="breakthrough">
                    <p><strong>Clinical Breakthrough:</strong> Recent studies show MEK inhibitors can achieve tumor shrinkage rates not seen with traditional chemotherapy, while preserving cognitive function and quality of life.</p>
                </div>
            </div>
            
            <div class="section">
                <h2><i class="fas fa-microscope"></i> Next-Generation Targeted Approaches</h2>
                <p>These advanced therapies are currently in clinical development:</p>
                
                <h3>Advanced RAF Inhibitors <span class="status-badge clinical-trial">PHASE 1/2</span></h3>
                <p><strong>PLX8394 & TAK580:</strong> "Paradox-breaker" RAF inhibitors designed specifically for BRAF fusion tumors. Unlike traditional BRAF inhibitors, these can effectively target fusion-driven cancers without causing paradoxical activation.</p>
                
                <h3>FGFR Inhibitors <span class="status-badge emerging">EMERGING</span></h3>
                <p><strong>Erdafitinib, Ponatinib:</strong> For PA with FGFR1 mutations (found in 15% of adult cases, particularly extra-cerebellar locations). FGFR1 mutations are associated with worse outcomes, making this a critical therapeutic target.</p>
                
                <h3>Combination Immunotherapy <span class="status-badge emerging">EMERGING</span></h3>
                <p>Since many PAs are immunologically "cold," combining targeted therapy with immune checkpoint inhibitors or novel immune activators may enhance effectiveness.</p>
            </div>
            
            <div class="section">
                <h2><i class="fas fa-dna"></i> Emerging Cellular & Gene Therapies</h2>
                <p>These cutting-edge approaches show promise but require further development:</p>
                
                <div class="card-container">
                    <div class="card">
                        <div class="card-header">CAR-T Cell Therapy <span class="status-badge emerging">PROOF-OF-CONCEPT</span></div>
                        <div class="card-body">
                            <p><strong>Current Status:</strong> Breakthrough results in related brain tumors (GD2 CAR-T for diffuse midline gliomas, B7-H3 CAR-T for DIPG)</p>
                            <p><strong>PA Application:</strong> Researchers are developing PA-specific CAR-T approaches targeting BRAF fusion proteins</p>
                            <p><strong>Timeline:</strong> Early clinical trials expected within 2-3 years</p>
                            <a href="https://www.cancer.gov/news-events/cancer-currents-blog/2025/car-t-cell-therapy-gd2-diffuse-midline-gliomas" class="trial-link emerging" target="_blank">Learn About Brain Tumor CAR-T Success</a>
                        </div>
                    </div>
                    
                    <div class="card">
                        <div class="card-header">CRISPR Gene Editing <span class="status-badge preclinical">PRECLINICAL</span></div>
                        <div class="card-body">
                            <p><strong>Concept:</strong> Direct correction of BRAF fusion genes within tumor cells</p>
                            <p><strong>Status:</strong> Promising preclinical results at major research centers</p>
                            <p><strong>Challenge:</strong> Delivery to brain tissue and ensuring safety</p>
                            <p><strong>Timeline:</strong> 5-7 years to clinical trials</p>
                        </div>
                    </div>
                </div>
            </div>
            
            <div class="section">
                <h2><i class="fas fa-heartbeat"></i> Advanced Monitoring & Prevention</h2>
                <p>Novel approaches to detect progression and optimize treatment:</p>
                
                <div class="card-container">
                    <div class="card">
                        <div class="card-header">Liquid Biopsy</div>
                        <div class="card-body">
                            <p><strong>Technology:</strong> Detection of circulating tumor DNA (ctDNA) in blood or cerebrospinal fluid</p>
                            <p><strong>Advantage:</strong> Can detect recurrence months before MRI changes</p>
                            <p><strong>Current Status:</strong> Research tools becoming clinically available</p>
                        </div>
                    </div>
                    
                    <div class="card">
                        <div class="card-header">Pharmacogenomic Testing</div>
                        <div class="card-body">
                            <p><strong>Purpose:</strong> Optimize drug dosing based on individual metabolism</p>
                            <p><strong>Relevance:</strong> Critical for MEK inhibitors which have narrow therapeutic windows</p>
                            <p><strong>Implementation:</strong> Increasingly standard in pediatric oncology</p>
                        </div>
                    </div>
                </div>
            </div>
            
            <div class="section">
                <h2><i class="fas fa-flask"></i> Clinical Trials & Research Access</h2>
                <p>How to access cutting-edge treatments:</p>
                
                <div class="table-container">
                    <table>
                        <thead>
                            <tr>
                                <th>Research Consortium</th>
                                <th>Focus Areas</th>
                                <th>Access Information</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Children's Oncology Group (COG)</td>
                                <td>Phase 3 selumetinib vs. chemotherapy</td>
                                <td><a href="https://www.childrensoncologygroup.org/clinicaltrials-136" target="_blank">COG Clinical Trials</a></td>
                            </tr>
                            <tr>
                                <td>Pediatric Neuro-Oncology Consortium (PNOC)</td>
                                <td>Novel targeted therapies</td>
                                <td><a href="https://pnoc.us/clinical-trials/" target="_blank">PNOC Trials</a></td>
                            </tr>
                            <tr>
                                <td>Children's Brain Tumor Network (CBTN)</td>
                                <td>Genomic analysis & precision medicine</td>
                                <td><a href="https://cbtn.org/" target="_blank">CBTN Resources</a></td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>
            
            <div class="action-plan">
                <h3>Evidence-Based Action Plan for Patients and Families</h3>
                <ol>
                    <li><strong>Comprehensive Molecular Testing</strong> - Ensure testing for KIAA1549-BRAF fusion, BRAF V600E mutation, and FGFR1 alterations</li>
                    <li><strong>Consider First-Line Targeted Therapy</strong> - For unresectable or progressive PA, discuss MEK inhibitors with your oncologist before traditional chemotherapy</li>
                    <li><strong>Enroll in Research Studies</strong> - Participate in tissue banking and clinical trials to access newest treatments and advance research</li>
                    <li><strong>Multidisciplinary Care</strong> - Ensure access to pediatric neuro-oncology, ophthalmology, endocrinology, and neuropsychology</li>
                    <li><strong>Quality of Life Focus</strong> - Prioritize functional outcomes and neurocognitive preservation in treatment decisions</li>
                    <li><strong>Connect with Support Networks</strong>:
                        <ul style="margin-top: 10px; margin-left: 20px;">
                            <li><a href="https://cbtf.org/" target="_blank">Children's Brain Tumor Foundation</a></li>
                            <li><a href="https://braintumor.org/" target="_blank">National Brain Tumor Society</a></li>
                        </ul>
                    </li>
                </ol>
            </div>
        </div>
        
        <footer>
            <p>Pilocytic Astrocytoma Treatment Guide | Updated with latest clinical evidence</p>
            <p><strong>Important:</strong> This information is for educational purposes only. Always consult with qualified neuro-oncologists for personalized medical advice. Treatment decisions should be made based on individual tumor characteristics, patient factors, and current clinical guidelines.</p>
        </footer>
    </div>
</body>
</html>